logo-loader
viewCello Health PLC

Cello Health 'making good headway' with decent organic growth

Mark Scott, chief executive of Cello Health plc (LON:CLL) tells Proactive Investors they enjoyed a good rise in half-year profits, driven by another six months of strong growth from its Cello Health division.

The company has two arms: Health, which provides expertise, processes, intellectual property and market knowledge spanning the pharmaceutical, biotechnology, diagnostics, healthcare equipment and consumer health sectors.

And Signal, which provides “digital, social media and branding expertise” to companies. This division used to be focused sectors such as technology and retail, but it has taken a much greater interest in health of late.

Quick facts: Cello Health PLC

Price: 129 GBX

AIM:CLL
Market: AIM
Market Cap: £136.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Cello Health reports good growth in profits and strong cash flow

Cello Health PLC's (LON:CLL) Mark Scott tells Proactive London they've seen good growth in profits and strong cash flow for the first half of the year said that he's confident about the rest of the year too. The group delivered net revenue of £54.5mln for the first six months of the year,...

on 18/9/19

2 min read